Table 1.
Clinical trials AR targeting agents in CRPC
| Agent | Phase | RESIST Response | PSA Response | Reference |
|---|---|---|---|---|
| Androgen and DHT lowering compounds | ||||
| Abiraterone | II (chemo naive) | 12/21 | 18/30 (60%) | JS De Bono, abs 5005, 2008 ASCO Annual Meeting |
| II (chemo refractory) | 3/8 | 14/35 (40%) | DC Danila, abs 5019, 2008 ASCO Annual Meeting | |
| II (chemo refractory) | 4/28 | 16/31 (52%) | JS De Bono, abs 5005, 2008 ASCO Annual Meeting | |
| III (open) | ||||
| Dutasteride | II (open) | |||
| Dustasteride + ketoconazole | II (keto sensitive) | 30/57 (53%) | M Taplin, abs 5068, 2008 ASCO Annual Meeting | |
| Dustasteride + ketoconazole | II (keto refractory) | 0/10 (8/10 with PSA decline) | AO Sartor, abs 257, 2007 Prostate Cancer Symposium | |
| Antiandrogens | ||||
| MDV-3100 | I/II | 13/14 | HI Scher, abs 5006, 2008 ASCO Annual Meeting. | |
| BMS-641988 | I | |||
| EGFR and HER2 Targeting Agents | ||||
| Erlotinib | II (closed) | |||
| Erlotinib + docetaxel | II (closed) | 0/8 | 5/22 | [65] |
| Gefitinib | II (closed) | 0 | 0/23 | [66] |
| Lapatinib | II (open) | 1/21 | YE Whang, abs 16037, 2008 ASCO Annual Meeting | |
| Trastuzumab | II (closed) | [67] | ||
| Pertuzumab | II | 0/30 (5/30 SD >23 wk) | 0/41 | [68] |
| SRC Inhibitors | ||||
| Dasatinib | II | 67% disease control | 1/36 | EY Yu, abs 5156, 2008 ASCO Annual Meeting |
| HDAC inhibitors | ||||
| Depsipeptide | 1/21, (6/21 SD > 4m) | 2/31 | C Parker, abs in J Clin Oncol (2007) 25(18_suppl) 15507 | |
| LBH589 | I | 0/8 | DE Rathkopf, abs 5152, 2008 ASCO Annual Meeting | |
| SAHA+DOC | I | 2/8 | DE Rathkopf, abs 5152, 2008 ASCO Annual Meeting | |
| HSP90 Inhibitors | ||||
| 17-AAG | II | 0/15 | EI Heath, abs in J Clin Oncol (2007) 25(18_suppl) 15553 | |